Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 3Thoracic 2Plasma cell 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Pancreatic Neoplasms 685Cholangiocarcinoma 114Biliary Tract Neoplasms 95Neoplasms 69Neoplasm Metastasis 66Gallbladder Neoplasms 61Colorectal Neoplasms 49Bile Duct Neoplasms 40Carcinoma, Non-Small-Cell Lung 37Adenocarcinoma 28Carcinoma, Hepatocellular 26Stomach Neoplasms 22Liver Neoplasms 21Colonic Neoplasms 21Ovarian Neoplasms 20Lung Neoplasms 19Breast Neoplasms 18Rectal Neoplasms 15Carcinoma, Pancreatic Ductal 15Pancreatic Adenocarcinoma 13Esophageal Neoplasms 13Sarcoma 12Carcinoma 11Small Cell Lung Carcinoma 10Urinary Bladder Neoplasms 9Gastrointestinal Neoplasms 9Advanced Pancreatic Cancer 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Recurrence 8

Interventions

ruxolitinib 2pembrolizumab 2abiraterone 2Imatinib Mesylate 2Gemcitabine 2Doxorubicin 2venetoclax 1trametinib 1rucaparib 1regorafenib 1ponatinib 1pertuzumab 1pemigatinib 1palbociclib 1olaparib 1neratinib 1motexafin gadolinium 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Gemcitabine × Gastrointestinal × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡